Coherus Oncology (CHRS) EBT Margin (2013 - 2026)
Coherus Oncology's (CHRS) quarterly EBT Margin came in at 233.08% in Q2 2026, up 20443.0% year-over-year from N/an in Q2 2025, and up 22.32% quarter-over-quarter from 300.04% in Q1 2026.
Powered by 
Analysis
Coherus Oncology (CHRS) EBT Margin (2013 - 2026) Analysis & Trends
Coherus Oncology has disclosed EBT Margin across 13 years of filings, most recently posting 233.08% for Q2 2026.
- In Q2 2026, EBT Margin rose 20443.0% year-over-year to 233.08%; the TTM figure through Jun 2026 stood at 316.37% (up 27138.0% YoY), while the FY2025 annual figure was 434.23%, up 38200.0% from the prior year.
- EBT Margin came in at 233.08% for Q2 2026 at Coherus Oncology, up from 300.04% in the prior quarter.
- In the past five years, EBT Margin ranged from a high of 53.67% in Q3 2023 to a low of 2947.83% in Q1 2024.
- Average EBT Margin over 5 years is 456.49%, with a median of 266.76% recorded in 2023.
- Year-over-year, EBT Margin slumped 271436 bps in 2024 and surged 232409 bps in 2025.
- Over 5 years, EBT Margin stood at 129.81% in 2022, then soared by 33 bps to 87.03% in 2023, then sank by 585 bps to 596.06% in 2024, then soared by 39 bps to 363.56% in 2025, then jumped by 36 bps to 233.08% in 2026.
- Per Business Quant data, the three most recent EBT Margin figures were 233.08% in Q2 2026, 300.04% in Q1 2026, and 363.56% in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 27.53% |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | -131.41% |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | 41.75% |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 35.61% |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | 35.78% |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | -528.97% |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 13.77% |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | 4.84% |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | -20,427.46% |
| 10 | Coherus Oncology | 209.00 Mn | 103.70 Mn | 10.07 Mn | -233.08% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -233.08% |
| Mar 31, 2026 | -300.04% |
| Dec 31, 2025 | -363.56% |
| Sep 30, 2025 | -384.73% |
| Jun 30, 2025 | -437.51% |
| Mar 31, 2025 | -623.74% |
| Dec 31, 2024 | -596.06% |
| Sep 30, 2024 | -786.50% |
| Jun 30, 2024 | -532.74% |
| Mar 31, 2024 | -2,947.83% |
| Dec 31, 2023 | -87.03% |
| Sep 30, 2023 | -53.67% |
| Jun 30, 2023 | -73.01% |
| Mar 31, 2023 | -233.47% |
| Dec 31, 2022 | -129.81% |
| Sep 30, 2022 | -190.76% |
| Jun 30, 2022 | -83.37% |
| Mar 31, 2022 | -159.83% |
| Dec 31, 2021 | -62.34% |
| Sep 30, 2021 | -46.70% |